» Articles » PMID: 34171094

Signaling Targets Related to Antiobesity Effects of Capsaicin: A Scoping Review

Overview
Journal Adv Nutr
Publisher Elsevier
Date 2021 Jun 25
PMID 34171094
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The search for new antiobesogenic agents is increasing because of the current obesity pandemic. Capsaicin (Caps), an exogenous agonist of the vanilloid receptor of transient potential type 1 (TRPV1), has shown promising results in the treatment of obesity. This scoping review aims to verify the pathways mediating the effects of Caps in obesity and the different methods adopted to identify these pathways. The search was carried out using data from the EMBASE, MEDLINE (PubMed), Web of Science, and SCOPUS databases. Studies considered eligible evaluated the mechanisms of action of Caps in obesity models or cell types involved in obesity. Nine studies were included and 100% (n = 6) of the in vivo studies showed a high risk of bias. Of the 9 studies, 66.6% (n = 6) administered Caps orally in the diet and 55.5% (n = 5) used a concentration of Caps of 0.01% in the diet. In vitro, the most tested concentration was 1 μM (88.9%; n = 8). Capsazepine was the antagonist chosen by 66.6% (n = 6) of the studies. Seven studies (77.8%) linked the antiobesogenic effects of Caps to TRPV1 activation and 3 (33.3%) indicated peroxisome proliferator-activated receptor (PPAR) involvement as an upstream connection to TRPV1, rather than a direct metabolic target of Caps. The main secondary effects of Caps were lower weight gain (33.3%; n = 3) or loss (22.2%; n = 2), greater improvement in lipid profile (33.3%; n = 3), lower white adipocyte adipogenesis (33.3%; n = 3), browning process activation (44.4%; n = 4), and higher brown adipocyte activity (33.3%; n = 3) compared with those of the control treatment. Some studies have shown that PPAR agonists modulate TRPV1 activity, and no study has evaluated the simultaneous antagonism of these 2 receptors. Consequently, further studies are necessary to elucidate the role of each of these signaling molecules in the antiobesogenic effects of Caps.

Citing Articles

The Many Facets of PPAR-γ Agonism in Obesity and Associated Comorbidities: Benefits, Risks, Challenges, and Future Directions.

Kounatidis D, Vallianou N, Rebelos E, Kouveletsou M, Kontrafouri P, Eleftheriadou I Curr Obes Rep. 2025; 14(1):19.

PMID: 39934485 DOI: 10.1007/s13679-025-00612-4.


PIK3CA mutations enhance the adipogenesis of ADSCs in facial infiltrating lipomatosis through TRPV1.

Chen H, Sun B, Gao W, Qiu Y, Wei W, Li Y iScience. 2024; 27(8):110467.

PMID: 39104411 PMC: 11298645. DOI: 10.1016/j.isci.2024.110467.


Natural products in atherosclerosis therapy by targeting PPARs: a review focusing on lipid metabolism and inflammation.

Zhang Y, Zhang X, Shi S, Ma C, Lin Y, Song W Front Cardiovasc Med. 2024; 11:1372055.

PMID: 38699583 PMC: 11064802. DOI: 10.3389/fcvm.2024.1372055.


Are We Ready to Recommend Capsaicin for Disorders Other Than Neuropathic Pain?.

Silva J, Santos E, Alvarez-Leite J Nutrients. 2023; 15(20).

PMID: 37892544 PMC: 10609899. DOI: 10.3390/nu15204469.


Traditional processing increases biological activities of Dendrobium offificinale Kimura et. Migo in Southeast Yunnan, China.

Zhou D, Zhao Y, Chen Z, Yan X, Zhao Y, Gao L Sci Rep. 2022; 12(1):14814.

PMID: 36045147 PMC: 9433373. DOI: 10.1038/s41598-022-17628-8.


References
1.
Ambrosino P, Soldovieri M, De Maria M, Russo C, Taglialatela M . Functional and biochemical interaction between PPARα receptors and TRPV1 channels: Potential role in PPARα agonists-mediated analgesia. Pharmacol Res. 2014; 87:113-22. DOI: 10.1016/j.phrs.2014.06.015. View

2.
Marshall N, Liang L, Bodkin J, Dessapt-Baradez C, Nandi M, Collot-Teixeira S . A role for TRPV1 in influencing the onset of cardiovascular disease in obesity. Hypertension. 2012; 61(1):246-52. DOI: 10.1161/HYPERTENSIONAHA.112.201434. View

3.
Kida R, Noguchi T, Murakami M, Hashimoto O, Kawada T, Matsui T . Supra-pharmacological concentration of capsaicin stimulates brown adipogenesis through induction of endoplasmic reticulum stress. Sci Rep. 2018; 8(1):845. PMC: 5770457. DOI: 10.1038/s41598-018-19223-2. View

4.
Lee G, Shin M, Yoon D, Kim A, Yu R, Park N . Topical application of capsaicin reduces visceral adipose fat by affecting adipokine levels in high-fat diet-induced obese mice. Obesity (Silver Spring). 2013; 21(1):115-22. DOI: 10.1002/oby.20246. View

5.
Li Q, Li L, Wang F, Chen J, Zhao Y, Wang P . Dietary capsaicin prevents nonalcoholic fatty liver disease through transient receptor potential vanilloid 1-mediated peroxisome proliferator-activated receptor δ activation. Pflugers Arch. 2013; 465(9):1303-16. DOI: 10.1007/s00424-013-1274-4. View